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Objectives The aim of this study was to test the hypothesis that, without diagnostic changes in serum creatinine, increased
neutrophil gelatinase-associated lipocalin (NGAL) levels identify patients with subclinical acute kidney injury
(AKI) and therefore worse prognosis.
Background Neutrophil gelatinase-associated lipocalin detects subclinical AKI hours to days before increases in serum creati-
nine indicate manifest loss of renal function.
Methods We analyzed pooled data from 2,322 critically ill patients with predominantly cardiorenal syndrome from 10
prospective observational studies of NGAL. We used the terms NGAL() or NGAL() according to study-specific
NGAL cutoff for optimal AKI prediction and the terms sCREA() or sCREA() according to consensus diagnostic
increases in serum creatinine defining AKI. A priori-defined outcomes included need for renal replacement ther-
apy (primary endpoint), hospital mortality, their combination, and duration of stay in intensive care and in-
hospital.
Results Of study patients, 1,296 (55.8%) were NGAL()/sCREA(), 445 (19.2%) were NGAL()/sCREA(), 107 (4.6%)
were NGAL()/sCREA(), and 474 (20.4%) were NGAL()/sCREA(). According to the 4 study groups, there
was a stepwise increase in subsequent renal replacement therapy initiation—NGAL()/sCREA(): 0.0015% ver-
sus NGAL()/sCREA(): 2.5% (odds ratio: 16.4, 95% confidence interval: 3.6 to 76.9, p  0.001), NGAL()/
sCREA(): 7.5%, and NGAL()/sCREA(): 8.0%, respectively, hospital mortality (4.8%, 12.4%, 8.4%, 14.7%,
respectively) and their combination (4-group comparisons: all p  0.001). There was a similar and consistent
progressive increase in median number of intensive care and in-hospital days with increasing biomarker positiv-
ity: NGAL()/sCREA(): 4.2 and 8.8 days; NGAL()/sCREA(): 7.1 and 17.0 days; NGAL()/sCREA(): 6.5 and
17.8 days; NGAL()/sCREA(): 9.0 and 21.9 days; 4-group comparisons: p  0.003 and p  0.040, respec-
tively. Urine and plasma NGAL indicated a similar outcome pattern.
Conclusions In the absence of diagnostic increases in serum creatinine, NGAL detects patients with likely subclinical
AKI who have an increased risk of adverse outcomes. The concept and definition of AKI might need re-assessment.
(J Am Coll Cardiol 2011;57:1752–61) © 2011 by the American College of Cardiology Foundation
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April 26, 2011:1752–61 NGAL and Outcome in Cardiorenal SyndromeThe current concept and diagnosis of acute kidney injury
(AKI) are mainly based on diagnostic increases in serum
creatinine indicating loss of excretory renal function. Acute
kidney injury is then classified according to either the renal
risk (R), injury (I), failure (F), loss of renal function (L), end
stage renal disease (E) classification (RIFLE) (1) or AKI
etwork consensus criteria (2). Although such diagnosis of
KI is of prognostic relevance (3,4), it is delayed by 24 to
2 h compared with diagnosis by means of novel renal
iomarkers of tubular injury like neutrophil gelatinase-
ssociated lipocalin (NGAL) (5–7).
Neutrophil gelatinase-associated lipocalin fulfills many
haracteristics for an ideal biomarker for AKI. It was
iscovered with unbiased transcriptomic approaches (8,9); it
s rapidly induced and released from the injured distal
ephron in experimental models and human disease
5,9,10); its urine and plasma concentrations increase pro-
ortionally to severity and duration of renal injury (9,11,12);
ts concentration rapidly decreases with attenuation of renal
njury (13); and it is readily and easily measured in plasma
11) and urine (12). Finally, NGAL seems to play a key role
n early AKI and local iron transport (10,14,15), providing
iologic plausibility for its use as an AKI biomarker.
Several studies have found NGAL useful compared with
arly measurements of serum creatinine in AKI (6,7,16,17).
n response to renal injury, increases in NGAL levels
redict AKI 24 to 72 h before diagnostic creatinine in-
reases (5–7,11,12) and are of prognostic value (18). Despite
he aforementioned characteristics, the ability of NGAL to
redict the development of AKI seems imperfect (19,20).
owever, the predictive value of NGAL improves with
ncreasing RIFLE class of AKI (21), suggesting that limi-
ations in its accuracy reflect the use of an imperfect test
serum creatinine) as study endpoint. Serum creatinine
equires several hours to days to accumulate, it increases in
erum only after 50% or more of renal function is lost, and
ts concentration is affected by multiple confounding factors
22). Accordingly, we hypothesized that, without diagnostic
ncreases in serum creatinine, NGAL() patients might
ave likely subclinical AKI and therefore carry a worse
rognosis—as indicated by the need for renal replacement
herapy (RRT) and other patient-centered outcomes—than
GAL() patients. We tested this hypothesis by analyzing
ooled data from multiple centers and determined the
linical outcomes of subjects classified according to their
GAL and serum creatinine concentrations.
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ogy and Hypertension, Cincinnati Children’s Hospital, Cincinnati, Ohio; §§Depart-
ment of Clinical Biochemistry, KAT General Hospital, Athens, Greece;  Depart-
ent of Physiology and Pharmacology, Karolinska Institute and Department of
edical Sciences, Clinical Chemistry, Uppsala University, Stockholm, Sweden; and
he ¶¶Department of Medicine, Divisions of Nephrology, Allergy, Pulmonary, and
ritical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
full list of author disclosures can be found at the end of this paper. Drs. Haase,
evarajan, and Haase-Fielitz contributed equally to this work.
Manuscript received September 1, 2010; revised manuscript received November 1,C010, accepted November 9, 2010.ethods
e performed a summary patient-
evel analysis with summarized
ata from each study (see data
ollection form in the Online
ppendix). For this purpose, we
sed data from a previously de-
cribed multicenter data pool
reated to study the predictive
alue of NGAL for AKI defined
y increases in serum creatinine
18). This pool was extended by
ewly identified clinical studies
n NGAL as biomarker of AKI.
ndividual patient data were not
vailable. Figure 1 displays the results of the search and data
cquisition strategies.
ata pool creation. Two investigators (A.H.F. and
.R.M.) independently searched PUBMED, EMBASE,
ENTRAL, and abstracts submitted to the Congress of the
merican Society of Nephrology. They identified relevant
rticles or abstracts and independently screened studies for
nclusion (Fig. 1). Selection was restricted to published
rospective cohort studies in humans investigating the
iagnostic and prognostic ability of NGAL for AKI, need
or renal replacement therapy, and in-hospital mortality.
ach independent biomarker study was approved by a local
nstitutional review board, and all participants gave written
nformed consent. All studies originally were designed to
xamine the diagnostic accuracy of NGAL level, prospec-
ively enrolled consecutive patients, and had clearly defined
nrollment and exclusion criteria, and laboratory/research
ersonnel and clinicians were blinded. All studies enrolled
epresentative patient cohorts who might receive the test in
linical practice. Included studies had similar sample collec-
ion and processing and provided full datasets.
GAL measurement and AKI definition. For the pur-
ose of this study, we included urine and plasma NGAL
alues and reported those in a combined fashion and
eparately. We asked each author to use the measurement
erformed at least 24 to 48 h before the diagnosis of AKI
hen NGAL was measured more than once or, when no
erum creatinine increase occurred, to use NGAL measured
t intensive care unit (ICU) admission or 2 to 6 h after any
ew renal insult. We defined AKI according to the RIFLE
lassification (1) as an increase in serum creatinine 50%
rom baseline to peak value within 7 days of admission to
he ICU on the basis of daily serum creatinine measurement
RIFLE class R or worse). We chose RIFLE over the AKI
etwork classification (2) because of its greater sensitivity
23). Baseline serum creatinine was defined as the concen-
ration obtained at outpatient departments or at hospital
dmission in cardiac surgery patients or at ICU admission in
ritically ill patients when previous values were not available.
Abbreviations
and Acronyms
AKI  acute kidney injury
ICU  intensive care unit
NGAL  neutrophil
gelatinase-associated
lipocalin
RIFLE  renal risk, injury,
failure, loss of renal
function, end stage renal
disease classification
RRT  renal replacement
therapy
sCREA  serum creatininehronic kidney disease was defined as an estimated glomer-
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NGAL and Outcome in Cardiorenal Syndrome April 26, 2011:1752–61ular filtration rate 60 ml/min/1.73 m2 calculated with the
implified Modification of Diet in Renal Disease study
ormula (24) in adults or the simplified Schwartz formula in
hildren (25). Renal replacement therapy (RRT) was initi-
ted on the basis of center- and physician-specific practice,
nd no patient received RRT for nonrenal indications.
We applied the term “NGAL()” or “NGAL()” to
ndicate the absence or presence of tubular injury, as defined
y each study-specific NGAL cutoff value for the optimal
ombination of sensitivity and specificity for AKI prediction
18). The early “research-based” urine or plasma NGAL
nzyme-linked immunosorbent assays were internally valid,
ut their cutoff values were not transferable to other
nzyme-linked immunosorbent assays or immunoblots
sed. We used the term serum creatinine “sCREA()” or
sCREA()” to indicate the absence or presence of mani-
est AKI as defined by RIFLE criteria.
Patients were classified as follows: 1) NGAL()/
CREA(); 2) NGAL()/sCREA(); 3) NGAL()/
CREA(); and 4) NGAL()/sCREA().
atient outcomes. For the present study, we invited each
nvestigator to analyze data from their individual patient
ohort and return a specifically designed data collection
orm (Online Appendix) recording demographic data, in-
ormation on comorbidities, and a priori-defined patient
utcomes including renal replacement therapy initiation
primary endpoint), in-hospital mortality, the combination
f both and the length of ICU and hospital stay and
ccording to the NGAL of patients and serum creatinine
Figure 1 Flow of Study Selection
NGAL  neutrophil gelatinase-associated lipocalin; RRT  renal replacement theratates as defined in the preceding text. statistical analysis. All analyses followed a preset statisti-
al analysis plan, which included the aforementioned a
riori-defined hypothesis. Data were tested on normality
ith histograms. When data were normally distributed,
nalysis of variance was used to compare numerical data of
atients according to the defined groups. Otherwise, non-
arametric testing was used (Kruskal-Wallis test for
-group comparison, Mann-Whitney test for 2-group com-
arison). Fisher exact test or the chi-square test was applied
or comparison of categorical values as appropriate. Analysis
as repeated after weighing of the study endpoints accord-
ng to the relative sample size of each study. We used SPSS
version 16.0, SPSS, Inc., Chicago, Illinois). A 2-sided
value 0.05 was considered to be statistically significant.
esults
en (6,7,11,12,19,20,26–29) of 15 authors contacted re-
urned complete datasets. The reasons for exclusion are
eported in Figure 1.
We obtained data on 2,322 critically ill patients from
merica, Europe, and Australia (Table 1), with the majority
aving cardiorenal syndrome (30). The incidence of AKI
anged from 15% to 49%. Characteristics and baseline peak
GAL levels of patients are shown in Table 2. The
ajority of patients were NGAL()/sCREA(), whereas
5% of patients developed AKI on the basis of the RIFLE
efinition, 3% required renal replacement therapy, and 8%
ied in-hospital. In patients with diabetes, NGAL()/py.CREA() status was less common than NGAL()/
sa
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April 26, 2011:1752–61 NGAL and Outcome in Cardiorenal SyndromesCREA(). Chronic kidney disease was similarly common
among NGAL()/sCREA() (11.0%) and NGAL()/
CREA() (10.6%) patients.
Figure 2A shows the proportion of patients in each study
ccording to NGAL/sCREA status, with approximately
0% of all patients being NGAL()/sCREA(). Over-
ll, 43% of patients diagnosed with AKI by means of
GAL would have been classified as non-AKI using
reatinine criteria alone (Fig. 2B).
atient outcomes. Treatment with RRT increased from
.0015% in biomarker-negative patients to 2.5% in
GAL()/sCREA() patients, 7.5% in NGAL()/
CREA() patients, and 8.0% in NGAL()/sCREA()
atients (4-group comparison: p  0.001) (Fig. 3). Specif-
cally, more patients with NGAL()/sCREA() status
eeded RRT initiation than patients with NGAL()/
CREA() status (odds ratio: 16.4, 95% confidence inter-
al: 3.6 to 76.9, p  0.001). Additional endpoints compar-
ng these patient groups are shown in Table 3.
Hospital mortality doubled from biomarker negative
atients to NGAL()/sCREA() status and more than
ripled in patients positive for both biomarkers (4-group
omparison: p  0.001) (Fig. 3). More NGAL()/
CREA() patients (69 of 445; 15.5%) developed the
omposite endpoint of RRT initiation or in-hospital mor-
ality when compared with biomarker negative patients (63
Characteristics of StudiesTable 1 Characteristics of Studies
First Author (Ref. #) Population Type AKI Etiology AK
Dent et al. (11) Children Cardiac surgery
Bennett et al. (12) Children Cardiac surgery
Krawczeski et al. (29) Children Cardiac surgery
Zappitelli et al. (27) Children Critically ill
Cruz et al. (6) Adults Critically ill
Haase-Fielitz et al. (7) Adults Cardiac surgery
Koyner et al. (26) Adults Cardiac surgery
Wagener et al. (19) Adults Cardiac surgery
Martensson et al. (28) Adults Critically ill
Siew et al. (20) Adults Critically ill
*With neutrophil gelatinase-associated lipocalin (NGAL) measured at least 24 to 48 h before the
insult and excluding patients with urinary tract infection. †Preceding the diagnosis of AKI on th
R or worse (1).
Baseline Characteristics of PatientsTable 2 Baseline Characteristics of Patients
NGAL()/sCREA() NGAL()/sCRE
n 1,296 (55.8%) 445 (19.2%)
Age, yrs 47.2 (4.5–61.6) 53.5 (3.6–60.7
Female 475 (36.7%) 181 (40.7%)
Chronic kidney disease* 143 (11.0%) 47 (10.6%)
Diabetes mellitus 113 (8.7%) 78 (17.5%)
Congestive heart failure 67 (5.2%) 51 (11.5%)
Peak NGAL, ng/ml 59 (20–97) 213 (117–1,1
n 2,322. Values given as n (%) or median (25th to 75th percentiles). *As defined by estimated gl
24,25).
NGAL  neutrophil gelatinase-associated lipocalin; sCREA  serum creatinine.f 1,296; 4.9%) (p  0.001). A greater proportion of
GAL()/sCREA() patients (84 of 474; 17.7%) reached
he combined endpoint of RRT initiation and in-hospital
ortality compared with patients negative for both bio-
arkers (odds ratio: 4.2, 95% confidence interval: 3.0 to 6.0,
 0.001).
The NGAL()/sCREA() patients had a 70% longer
tay in the ICU compared with patients negative for both
iomarkers (p  0.026) (Fig. 4A). There was a gradual
ncrease in median length of stay in the ICU with the shortest
uration (in days, median [25th to 75th percentile]) for
GAL()/sCREA() patients (4.2 [2.2 to 6.4]), low inter-
ediate duration for NGAL()/sCREA() patients (6.5 [3.0
o 11.7]), high intermediate duration for NGAL()/
CREA() patients (7.1 [5.4 to 10.3]), and longest duration
or NGAL()/sCREA() patients (9.0 [8.0 to 14.0]) (p 
.003; 4-group comparison).
The NGAL()/sCREA() patients spent twice as long
n hospital compared with patients negative for both renal
iomarkers (p  0.16) (Fig. 4B). The shortest hospital stay
in days, median [25th to 75th percentile]) was for
GAL()/sCREA() patients (8.8 [7.7 to 19.0]) with low
ntermediate values for NGAL()/sCREA() patients
17.0 [8.4 to 24.2]), high intermediate values for
GAL()/sCREA() patients (17.8 [5.1 to 26.4]), and
ence
No. of Patients*
NGAL Measurement,† hUrine NGAL Plasma NGAL
— 125 48
194 — 48
189 358 48
33 — 36
— 279 24
— 100 48
52 51 36
383 — 36
64 64 48
430 — 48
is of acute kidney injury (AKI) or at intensive care unit admission several hours after new renal
of renal risk, injury, failure, loss of renal function, or end stage renal disease classification class
NGAL()/sCREA() NGAL()/sCREA() p Value
107 (4.6%) 474 (20.4%) —
59.0 (4.4–67.3) 50.4 (3.6–66.8) 0.89
42 (39.3%) 210 (44.3%) 0.028
16 (15.0%) 81 (17.1%) 0.030
28 (26.2%) 29 (6.1%) 0.001
10 (9.4%) 14 (3.0%) 0.001
69 (21–118) 354 (208–1,888) 0.001
ar filtration rate60 ml/min/1.73 m2 with the modification of diet in renal disease study formulaI Incid
36%
49%
35%
30%
28%
23%
16%
15%
34%
19%
diagnosA()
)
24)
omerul
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NGAL and Outcome in Cardiorenal Syndrome April 26, 2011:1752–61Figure 2 Proportions of Patients
(A) Proportion of patients according to biomarker states. (B) Proportion of neutrophil gelatinase-associated lipocalin (NGAL) ()/serum creatinine (sCREA) () patients
in relation to the proportion of patients diagnosed to have acute kidney injury by conventional creatinine-based criteria (renal risk, injury, failure, loss of renal function,
end stage renal disease classification (1) and NGAL positivity. The formula used was:
NGAL/ sCREA renal impairment identified by NGAL
NGAL/ sCREA  NGAL/ sCREA  NGAL/ sCREA  all renal impairment     
tp
i
N
D
K
o
d
n
m
n
N
t
N
m
p
R
p
r
N
w
p
u
a
R
3
i
m
o
(
p
H
f
t
s
1757JACC Vol. 57, No. 17, 2011 Haase et al.
April 26, 2011:1752–61 NGAL and Outcome in Cardiorenal Syndromelongest stay for NGAL()/sCREA() patients (21.9 [15.8
o 29.9]) (p  0.040; 4-group comparison).
Table 4 presents outcomes according to urine versus
lasma NGAL, confirming a similar outcome pattern
ndependent of the biological material used to measure
GAL.
iscussion
ey study findings. We conducted a multicenter analysis
f pooled data to explore the prognostic value of AKI
etected by NGAL. We hypothesized that, without diag-
ostic increase in serum creatinine, NGAL() patients
ight have likely subclinical AKI and carry a worse prog-
osis than NGAL() patients. We found that a positive
GAL finding carried a similar risk of adverse outcome
han a positive creatinine finding. We also found that
GAL()/sCREA() tests identified approximately 40%
ore AKI cases than sCREA() alone and that these
atients were at greater risk of longer ICU and hospital stay,
RT, and death compared with control subjects. As ex-
ected, NGAL()/sCREA() patients had the greatest
isk of adverse outcomes. A smaller group of patients were
GAL()/sCREA(), implying loss of renal function
Figure 3 Incidence of Events
Incidence of RRT initiation, in-hospital morality, and a combination of both
according to NGAL and sCREA. There was a stepwise increase in all outcomes.
Abbreviations as in Figures 1 and 2.
Value of NGAL Complements Prognosis inP ti nts Without Diagnostic Creatinine I creaseTable 3 Value of NGAL Complements P ognosis inPatients Without Diagnostic Creatinine Increase
Outcome
NGAL/sCREA vs.
NGAL/sCREA p Value
Need for RRT initiation 16.4 (3.6–76.9) 0.001
In-hospital mortality 2.8 (1.9–4.1) 0.001
Need for RRT initiation/
in-hospital mortality
3.6 (2.5–5.2) 0.001
ICU stay, days* 2.9 0.026
Hospital stay, days* 8.2 0.16
Values given as odds ratio (95% confidence interval) or n. *Median difference.p
CI  confidence interval; ICU  intensive care unit; OR  odds ratio; RRT  renal replacement
therapy; other abbreviations as in Table 2.ithout evidence of acute tubular injury. Outcome of these
atients was intermediate in severity. Finally, NGAL in the
rine or plasma showed a similar pattern for the outcomes
ssessed.
elation to previous studies. AKI might affect 20% to
0% of hospitalized patients; it carries significant costs and
s independently associated with increased morbidity and
ortality (31,32). Our study is consistent with other reports
n the prognostic importance of serum creatinine increase
31,32). Similarly, NGAL has been repeatedly shown to
redict the need for RRT and mortality in AKI (7,12,16).
owever, previous studies have also shown that NGAL
ailed to reliably predict changes in serum creatinine, even
hough its predictive value improved with increasing AKI
everity (21).
Until now, the aforementioned findings have been inter-
Figure 4 Median LOS in ICU
Length of stay (LOS) stratified by NGAL and sCREA in the intensive care unit
(ICU) (A) and in-hospital (B). There was a stepwise increase in median LOS in
ICU and in-hospital. Abbreviations as in Figures 1 and 2.reted as reflecting the shortcomings of NGAL as a biomarker
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NGAL and Outcome in Cardiorenal Syndrome April 26, 2011:1752–61(20). An alternative explanation, however, is that the limitation
lies with serum creatinine as the diagnostic standard and the
different nature of the signal provided. Thus, NGAL indicates
tubular injury that precedes renal functional loss by several
days, and serum creatinine indicates subsequent loss of renal
excretory function. Our findings suggest that a state of AKI
likely exists when NGAL is increased, independent of serum
creatinine increases.
Previous work supports the biological plausibility of the
aforementioned notion and suggests that serum creatinine is
a delayed, low-sensitivity, and could be a misleading bio-
marker of AKI (5,7), affected by many confounding factors
22). In this regard, several studies (33,34,35) suggest an
nalogy between the troponin/creatine kinase and the
GAL/creatinine relationship with a novel, more-sensitive
iomarker identifying previously undetected organ injury.
his increased diagnostic sensitivity of troponin is clinically
elevant (33) and, in the field of cardiology, has altered the
efinition, diagnosis, and management of acute myocardial
nfarction. This concept might similarly apply to NGAL.
ignificance of study findings. Potential explanations of
tudy findings are given in Table 5. Our study suggests that
cute tubular damage might occur without detectable loss of
xcretory function (and vice versa) and might predict worse
linical outcome and that NGAL and serum creatinine
eflect distinct pathophysiological events. A changed view of
KI might change clinical practice and its treatment.
etection of elevated NGAL might enable more rapid
Outcome According to Urine NGAL Versus Plasma NGALTable 4 Outcome According to Urine NGAL Versus Plasma NGA
NGAL()/sCREA() NGAL(
Urine NGAL (n  1,345) 758 (56.4%) 30
Need for RRT initiation 2 (0.003%)
In-hospital mortality 35 (4.6%) 3
ICU stay, days 4.2 (2.1–8.5) 7.
Hospital stay, days 8.8 (7.2–18.8) 17.
Plasma NGAL (n  977) 538 (55.1%) 13
Need for RRT initiation 0 (0%)
In-hospital mortality 27 (5.0%) 1
ICU stay, days 4.0 (2.2–5.4) 6.
Hospital stay, days 9.7 (7.3–20.3) 14.
Values given as n (%) or median (25th to 75th percentiles).
Abbreviations as in Tables 2 and 3.
Possible Combinations of NGAL and sCREA StatusTable 5 Possible Combinations of NGAL and sCREA Status
Diagnostic Increase of NGAL
(Subclinical AKI, Days Before Diagnostic
Serum Creatinine Increase)
Diagnostic Increase of sCREA
(Manifest AKI)
Positive Positive
Positive Negative
Negative Positive
Negative Negative
AKI as defined by the renal risk, injury, failure, loss of renal function, end stage renal disease classi
RT, prolonged length of stay in the ICU or in the hospital.
Abbreviations as in Tables 1, 2, and 3.onventional interventions or introduction of novel thera-
ies to prevent or effectively treat such otherwise undetected
KI (30). Novel renal biomarkers might facilitate standard-
zation of early diagnosis and treatment. By contrast, a
ormal NGAL result might inform clinical decision-
aking and lead to improved use of hospital resources.
For the first time, we identified a substantial group of
atients who do not fulfill current creatinine-based consen-
us criteria for AKI yet are likely to have acute tubular
njury. We further demonstrated that these patients have a
igher risk of adverse outcomes, including death. These
atients might benefit from medical attention. Such medical
ttention might carry a greater likelihood of success, because
hanges in NGAL levels are rapid (hours) and changes in
erum creatinine slow (days). Patients with AKI might, by
nalogy with acute myocardial infarction (34), now receive
arly intervention (13,36,37). In addition, our findings
uggest that the definition of AKI should be refined,
otentially by the application of criteria that include novel
enal biomarkers such as NGAL.
Because NGAL-positive AKI—with or without the de-
elopment of sCREA()—is associated with poor patient
utcomes, serum creatinine fails to identify likely AKI in
ome patients who are at increased risk of death. This
bservation does not imply that serum creatinine should
e discarded as a marker of AKI. In fact, in most study
atients, subclinical tubular injury preceded detectable
ecreases of renal function; and when both occurred
REA() NGAL()/sCREA() NGAL()/sCREA()
%) 63 (4.7%) 217 (16.1%)
) 2 (3.2%) 16 (7.4%)
%) 3 (4.8%) 30 (13.8%)
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Patient
Outcomes* Potential Explanations of Study Findings
Worse Subclinical AKI, manifest AKI
Worse Subclinical AKI
Worse False negative NGAL/glomerular impairment without tubular
injury (pre-renal azotemia)/NGAL negative because
measurement was days before serum creatinine increase
Better No subclinical AKI, no manifest AKI
criteria (1), or AKI Network classification (2). *e.g., need for RRT initiation; mortality, death duringL
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April 26, 2011:1752–61 NGAL and Outcome in Cardiorenal Syndrometogether, clinical outcomes were worse. Thus, knowledge
of NGAL levels modifies prognostic assessment not only
in patients without an increase in serum creatinine but
also in patients with creatinine-based consensus criteria
for AKI. In these patients, however, AKI could only be
diagnosed late, making any treatment less likely to succeed.
There might be alternative explanations for the NGAL()/
sCREA() syndrome: Some of these patients might de-
velop loss of renal function after the consensus period of
7 days, and NGAL identified these patients more than 1
week before such loss of function. A small number of
patients might have died soon after NGAL testing,
possibly too early to manifest sCREA() AKI. Finally,
in a minority of patients, NGAL might have simply acted
as a marker of inflammation, 1 of the most important risk
factors for AKI.
We also identified a very small subgroup of patients with
no biomarker evidence of tubular injury but loss of excretory
function: NGAL()/sCREA(), 4.6%. Because NGAL,
n contrast to serum creatinine, was not consistently serially
easured, this observation might represent a false negative
nding. However, “pre-renal azotemia” (loss of function
ithout tubular injury) might also explain such findings
38). Therefore, if NGAL was truly negative, these patients
ight represent a subgroup currently referred to as having
re-renal azotemia (39). In our study, NGAL()/
CREA() status was more common in elderly and diabetic
atients and was still associated with a 2-fold increase in
isk of developing the composite outcome of death and
enal replacement therapy, compared with patients neg-
tive for both biomarkers (NGAL/sCREA). This is
onsistent with recent reports associating even transient
zotemia with a greater risk of death (40). Neutrophil
elatinase-associated lipocalin might now help identify
ome of these patients.
Although it is known that NGAL concentration is
omewhat increased in patients with diabetic nephropathy
41–43), there is no information on acute NGAL respon-
iveness. By contrast, it remains unknown whether patients
n the NGAL()/sCREA() subgroup did not have active
ubular damage, because no biopsies were performed. How-
ver, there is evidence from animal experiments that pre-
enal azotemia does not translate into tubular damage or
etection of NGAL in the urine or plasma (44,45).
Finally, NGAL detected approximately 40% of patients
ith probable AKI who were missed by consensus criteria.
his proportion is similar to that identified by troponin in
ubjects with myocardial injury missed by conventional
iomarkers (30).
This study cannot determine the source of NGAL, but
he kidney should be the major source of NGAL. If plasma
GAL was produced outside the kidney and then filtered,
he proximal renal tubules would completely reabsorb
GAL with no or minimal urine NGAL levels (10). Also,
he decrease in glomerular filtration rate seen in AKI would
ecrease NGAL clearance, resulting in decreased urine iGAL and increased plasma NGAL. Therefore, NGAL
easured in the urine should either result largely from
njured and not reabsorbing proximal tubules or arise from
he injured distal nephron. Indeed, experimental evidence
upports this view that NGAL in plasma might predomi-
antly arise from the injured thick ascending tubules and the
ollecting ducts via back-leak from injured renal tissue—
gain reflecting renal damage. Neutrophil gelatinase-
ssociated lipocalin should be considered as a vigorous
utcome marker in AKI, on the basis of these results and
ur study findings with urine and plasma NGAL that
ndicated a very similar patient outcome pattern.
tudy strengths and limitations. This study has several
trengths. It is multicenter and involved more than 2,000
atients at risk of AKI; it used data collected independently
n different countries, assessed patients with diverse condi-
ions, and used different commercially available assays.
owever, it is retrospective in design, with all of the
nherent imperfections of such studies, and because no
ndividual patient data were obtained, meaningful meta-
egression analysis was not possible. Our results might be
ffected by selection on the basis of voluntary data contri-
ution. The direction and the magnitude of this potential
ias is unknown. Nonetheless, the findings show strength of
ssociation, temporality, consistency, biological plausibility
nd gradient, coherence with previous studies, and are
nalogous to other fields of biomarker investigations. These
eatures make it probable that the findings reflect a biolog-
cal phenomenon (46). Future prospective studies should
onfirm histopathological agreement of NGAL with tubu-
ar injury, shown in animal experiments, and explore the
rognostic value of other structural AKI biomarkers beyond
GAL (47), independent of serum creatinine. More im-
ortant, they should test whether NGAL-based early diag-
osis of AKI leads to the more successful and timelier
eployment of therapies that, until now, could only be deliv-
red late in the course of AKI (48,49) and improved outcomes.
onclusions
he study findings show that NGAL complements serum
reatinine in AKI diagnosis and prognosis. In a significant
roportion of patients at renal risk, acute tubular damage
ight occur without loss of excretory function. Such
GAL() patients are at greater risk of adverse outcomes,
ncluding death and renal replacement therapy, both in the
resence or absence of an increase in serum creatinine.
hese patients might be reasonably classified as having
KI, even though they do not fulfill current AKI consensus
riteria. Their detection and the size of their cohort justify
e-assessment of the concept and definition of AKI.
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